The Phosphorylated ATM Immunofluorescence Assay: A High-performance Radiosensitivity Assay to Predict Postradiation Therapy Overreactions.
Fiche publication
Date publication
juillet 2018
Journal
International journal of radiation oncology, biology, physics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BASTOGNE Thierry
Tous les auteurs :
Vogin G, Bastogne T, Bodgi L, Gillet-Daubin J, Canet A, Pereira S, Foray N
Lien Pubmed
Résumé
The ability to identify, before treatment, those patients who will overreact to radiation therapy would have sound positive clinical implications. By focusing on DNA double-strand breaks recognition and repair proteins after irradiation, we recently demonstrated that the maximal number of phosphorylated ATM (pATM) nuclear foci in the first hour (pATMmax) after ex vivo irradiation correlated with postradiation therapy toxicity severity. We performed additional analyses of our whole collection of fibroblast lines to refine the predictive performance of our assay.
Référence
Int. J. Radiat. Oncol. Biol. Phys.. 2018 Jul 1;101(3):690-693